4578:TSEOtsuka Holdings Co., Ltd. Analysis
Data as of 2026-05-20 - not real-time
¥11,310.00
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Otsuka Holdings trades at ¥11,310, comfortably above its 20‑day (¥11,018) and 50‑day (¥10,908) moving averages and well above the 200‑day level (¥9,205), confirming a bullish trend. The stock’s PE of 16.5 is markedly lower than the industry average of 27.2, while the price‑to‑book of 1.92 and a dividend yield of 1.26% with a modest payout ratio of 20% underscore attractive value and sustainable income. Revenue is expanding at 8.2% YoY with robust gross margins (~71%) and solid profitability (ROE ~13%), and the balance sheet remains strong – cash exceeds debt by over ¥340 bn despite a high debt‑to‑equity ratio.
Technical momentum is reinforced by a bullish MACD histogram (+13), a neutral RSI (~57), and an upside potential of roughly 9% toward the target mean price of ¥12,358. Volatility is elevated at ~26% over 30 days, but beta is near zero, indicating limited market‑wide price sensitivity. The “Extreme Greed” sentiment (89 on the fear‑greed index) aligns with the current price momentum, though decreasing volume suggests caution on short‑term rallies.
Technical momentum is reinforced by a bullish MACD histogram (+13), a neutral RSI (~57), and an upside potential of roughly 9% toward the target mean price of ¥12,358. Volatility is elevated at ~26% over 30 days, but beta is near zero, indicating limited market‑wide price sensitivity. The “Extreme Greed” sentiment (89 on the fear‑greed index) aligns with the current price momentum, though decreasing volume suggests caution on short‑term rallies.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Price above key moving averages and bullish MACD
- Undervalued valuation metrics (PE vs industry)
- Strong dividend sustainability
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Consistent revenue growth and high margins
- Attractive upside to analyst target price
- Robust cash position supporting continued investment
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Diversified pharmaceutical pipeline and global footprint
- Sustainable dividend and low beta indicating defensive profile
- Long‑term valuation appeal with solid balance sheet
Key Metrics & Analysis
Financial Health
Revenue Growth8.20%
Profit Margin14.96%
P/E Ratio16.5
ROE12.94%
ROA7.51%
Debt/Equity6.13
P/B Ratio1.9
Industry P/E27.2
Technical Analysis
TrendBullish
RSI57.3
Support¥10,440.00
Resistance¥11,660.00
MA 20¥11,018.00
MA 50¥10,908.30
MA 200¥9,205.49
MACDBullish
VolumeDecreasing
Fear & Greed Index89.18
Valuation
Target Price¥12,358.33
Upside/Downside9.27%
GradeUndervalued
TypeBlend
Dividend Yield1.26%
Risk Assessment
Beta0.02
Volatility25.82%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.